Immune Globulin Therapy (IVIG/SCIG) Coverage and Site-of-Service Criteria
Customize your policy alerts
Sign up for Premera Bluecross Policy 8.01.503 alerts
Get alerted when Policy 8.01.503 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, site-of-service review rules, and clinical coverage criteria for intravenous and injectable immune globulin products; intended for providers requesting prior authorization for immune globulin administration.
This policy has been revised and effective Aug. 1, 2026.
Site of Service Medical Necessity criteria do NOT apply to Alaska fully insured members; infusion/injection drug criteria apply instead.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.